ArticlePloS one2014
Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Pooled it
- Diagnostic Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-analysis.Cancer research communications · 2022Pooled it
- Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.Gastroenterology · 2021Trial
- THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.Cancer prevention research (Philadelphia, Pa.) · 2021Trial
- Aquaporin-1 differentiates intrahepatic cholangiocarcinoma from liver metastases of pancreatic ductal adenocarcinoma.Histopathology · 2026Article
- Clinical Significance of Cytokeratin 19-Fragments (CYFRA 21-1), Osteopontin (OPN) and Human Epididymis Protein 4 (HE4) in Pancreatic Adenocarcinoma.International journal of molecular sciences · 2026Article
- Quantitative immunohistochemistry analysis of pancreatic adenocarcinoma upregulated factor expression in pancreatic cancer and its prognostic significance.World journal of gastrointestinal oncology · 2025Article
- 5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.JCO precision oncology · 2024Article
- Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review.Journal of experimental & clinical cancer research : CR · 2024Review
- Circulating microRNAs in association with pancreatic cancer risk within 5 years.International journal of cancer · 2024Article
- Metabolomics for early pancreatic cancer detection in plasma samples from a Swedish prospective population-based biobank.Journal of gastrointestinal oncology · 2024Article
- Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Article
- Artificial intelligence in pancreatic cancer: diagnosis, limitations, and the future prospects-a narrative review.Journal of cancer research and clinical oncology · 2023Review
- Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.Iranian journal of medical sciences · 2023Article
- Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis.International journal of cancer · 2023Article
- The role of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer.Frontiers in immunology · 2023Review
- Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer.World journal of clinical oncology · 2022Article
- Artificial intelligence and imaging for risk prediction of pancreatic cancer: a narrative review.Chinese clinical oncology · 2022Review
- The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy.Cancers · 2022Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundThe clinical management of pancreatic cancer is severely hampered by the absence of effective screening tools.
methodsSixty-seven biomarkers were evaluated in prediagnostic sera obtained from cases of pancreatic cancer enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
resultsThe panel of CA 19-9, OPN, and OPG, identified in a prior retrospective study, was not effective. CA 19-9, CEA, NSE, bHCG, CEACAM1 and PRL were significantly altered in sera obtained from cases greater than 1 year prior to diagnosis. Levels of CA 19-9, CA 125, CEA, PRL, and IL-8 were negatively associated with time to diagnosis. A training/validation study using alternate halves of the PLCO set failed to identify a biomarker panel with significantly improved performance over CA 19-9 alone. When the entire PLCO set was used for training at a specificity (SP) of 95%, a panel of CA 19-9, CEA, and Cyfra 21-1 provided significantly elevated sensitivity (SN) levels of 32.4% and 29.7% in samples collected <1 and >1 year prior to diagnosis, respectively, compared to SN levels of 25.7% and 17.2% for CA 19-9 alone.
conclusionsMost biomarkers identified in previously conducted case/control studies are ineffective in prediagnostic samples, however several biomarkers were identified as significantly altered up to 35 months prior to diagnosis. Two newly derived biomarker combinations offered advantage over CA 19-9 alone in terms of SN, particularly in samples collected >1 year prior to diagnosis. However, the efficacy of biomarker-based tools remains limited at present. Several biomarkers demonstrated significant velocity related to time to diagnosis, an observation which may offer considerable potential for enhancements in early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.